sterilt vann b. braun leysir fyrir stungulyf
b.braun melsungen ag* - aqua ad iniectabilia - leysir fyrir stungulyf
natriumklorid b. braun leysir fyrir stungulyf 9 mg/ml
b.braun melsungen ag* - natrii chloridum - leysir fyrir stungulyf - 9 mg/ml
sterile water fresenius kabi, leysir fyrir stungulyf (sterilt vatten/vann/vand fresenius kabi) leysir fyrir stungulyf
fresenius kabi ab - aqua ad iniectabilia - leysir fyrir stungulyf
sterilt vatten baxter viaflo leysir fyrir stungulyf
baxter medical ab* - water for injection - leysir fyrir stungulyf
natriumklorid fresenius kabi leysir fyrir stungulyf 9 mg/ml
fresenius kabi ab - natrii chloridum - leysir fyrir stungulyf - 9 mg/ml
photobarr
pinnacle biologics b.v. - porfimer járn - barrett efri - Æxlishemjandi lyf - ljósvirknimeðferð (pdt) með photobarr er ætlað til: eyðingar hágæða dysplasia (hgd) í sjúklinga með barrett er vélinda (bo).
dynastat
pfizer europe ma eeig - parecoxibnatríum - verkir, eftir aðgerð - coxibs, antiinflammatory and antirheumatic products - til skammvinnrar meðhöndlunar á verkjum eftir aðgerð hjá fullorðnum.
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - mergæxli - Æxlishemjandi lyf - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
cutaquig stungulyf, lausn 165 mg/ml
octapharma ab - immunoglobulinum humanum inn - stungulyf, lausn - 165 mg/ml
piperacillin/tazobactam wh innrennslisstofn, lausn 4 g/0,5 g
williams & halls ehf. - piperacillinum natríum; tazobactamum natríum - innrennslisstofn, lausn - 4 g/0,5 g